Skip to search formSkip to main contentSkip to account menu

CD16+ CD56+ CD69+ Lymphocyte

Known as: CD16, CD56, CD69 Triple-Positive Activated Lymphocyte, TrPAL, Triple-Positive Activated Lymphocyte 
A population of activated lymphocytes that express CD16 (Fc-gamma receptor III), CD56 (neural cell adhesion molecule 1) and CD69 (early activation… 
National Institutes of Health

Related topics

Related topics

2 relations
Hematopoietic and Lymphoid TissueLymphoid Tissue

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
It’s TIME for a biomarker-driven approach to cancer immunotherapy
  • L. Emens
  • Journal of Immunotherapy for Cancer
  • 2016
  • Corpus ID: 16869160
Cancer immunotherapy has clearly taken its place in the clinic as one pillar of cancer care. Immune checkpoint blockade, which… 
2015
2015
Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.
3034 Background: TG4010 is an immunotherapy using an attenuated and modified poxvirus (MVA) coding for MUC1 and interleukin-2. A… 
2014
2014
Transgene Announces Topline Preliminary Results from Phase 2 b Part of TIME Trial with TG 4010 in Non-Small Cell Lung Cancer
  • 2014
  • Corpus ID: 166225312
Strasbourg, France, January 8, 2014 – Transgene SA (NYSE-Euronext: TNG) today announced topline preliminary results from the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)